Protective and therapeutic effects of metformin on gynecologic cancers | Zendy

Jee Young Hwang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Protective and therapeutic effects of metformin on gynecologic cancers

Author(s) -

Jee Young Hwang

Publication year - 2016

Publication title -

journal of gynecologic oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.358

H-Index - 37

eISSN - 2005-0399

pISSN - 2005-0380

DOI - 10.3802/jgo.2016.27.e61

Subject(s) - medicine , metformin , gynecologic cancer , oncology , therapeutic effect , pharmacology , ovarian cancer , cancer , insulin

Currently, in the aspect of drug repositioning, metformin which is the first line drug of choice for type 2 diabetes mellitus (T2DM) has been considered as a kind of therapeutic drug for gynecologic cancers based on its antitumor effects [1]. The main antitumor action of metformin occurs through activation of adenosine monophosphate activated protein kinase, which inhibits the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway stimulating cellular proliferation and activates p53. Additionally, it has been reported that metformin down-regulates cyclin D1 expression and telomerase activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research